Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million

2026-02-25 15:26:18 ET

On February 17, 2026, Great Point Partners disclosed a buy of 70,000 Apogee Therapeutics (NASDAQ:APGE) shares, an estimated $4.41 million trade based on quarterly average pricing.

According to an SEC filing dated February 17, 2026, Great Point Partners bought 70,000 additional shares of Apogee Therapeutics (NASDAQ:APGE) , with an estimated transaction value of $4.41 million based on the average closing price for the quarter. The fund’s quarter-end position value increased by $16.15 million, a figure that includes both the impact of new shares acquired and stock price appreciation.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of extended half-life monoclonal antibody therapeutics for inflammatory and immunological conditions. The company leverages proprietary biologic platforms to advance novel therapies for atopic dermatitis and COPD, positioning itself to address significant unmet medical needs. With a focused pipeline and expertise in antibody engineering, Apogee aims to establish a competitive edge in immunology-driven specialty markets.

Continue reading